Trial Profile
A Prospective, Open-label, Multicenter, Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone(VMP) for Initial Treatment in Patients With Multiple Myeloma Who do Not Undergo Autologous Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jul 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Janssen
- 19 Jun 2015 New trial record